REFRACTORY ACUTE LEUKEMIA
Clinical trials for REFRACTORY ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis study is testing a new three-drug combination (ziftomenib, venetoclax, and azacitidine) to find the safest and most effective dose for children and young adults whose acute leukemia has returned or not responded to other treatments. It focuses on patients whose cancer has sp…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for kids battling tough leukemia: experimental drug combo enters first human trial
Disease control Recruiting nowThis study aims to find a safe and effective dose of a two-drug combination (Hyper-CVAD and venetoclax) for children and young adults whose leukemia has returned or not responded to standard treatments. It will enroll up to 22 participants aged 2 to 21 years old. The main goal is…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug duo tested in fight against Tough-to-Treat leukemias
Disease control Recruiting nowThis study is testing whether combining two new drugs, revumenib and mezigdomide, is a safe and effective treatment for people with specific types of acute leukemia that have come back or not responded to prior therapy. It will involve about 52 participants aged 12 and older who …
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC